AUD1001 / Eli Lilly, Massachusetts Eye and Ear, Audion Therap - LARVOL DELTA

A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss. (PubMed, Nat Commun) - "DPOAE amplitudes, SNRs and distribution of categories did not change from baseline to 6 and 12 weeks, nor did SRTs and HHIA/E scores. Intratympanic delivery of LY3056480 is safe and well-tolerated; the trial's primary endpoint was not met."

Journal • P1/2 data • Otorhinolaryngology

VESTA: A Trial of LY3056480 in Patients With SNLH (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Audion Therapeutics BV | N=135 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Otorhinolaryngology